Tom Wickham joined Rubius as Vice President of Research and Development in October 2016 and was promoted in March 2019, to Senior Vice President of Discovery. He brings to Rubius 25 years of experience in preclinical research and development in oncology. Prior to joining Rubius, Tom served as Vice President, R&D at Merrimack Pharmaceuticals where he led preclinical through Phase 2 development of a targeted chemotherapy in breast cancer. Prior to Merrimack, Tom was Senior Director of Preclinical Pharmacology and led efforts at EMD Lexigen (now Merck-Serono) to advance immuno-oncology drugs through preclinical development and into Phase I trials. As Senior Director of Preclinical Sciences at GenVec, Inc. he led the advancement of a targeted gene delivery platform for oncology, cardiovascular, infectious disease and genetic disease applications.
Tom holds a B.S. in chemical/biomedical engineering from Carnegie Mellon University and a Ph.D. in biochemical engineering from Cornell University, and pursued his postdoctoral training at the Scripps Research Institute in the department of immunology.